These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26169860)

  • 1. Trials of obeticholic acid for non-alcoholic steatohepatitis.
    Musso G; Cassader M; Gambino R
    Lancet; 2015 Jul; 386(9988):27. PubMed ID: 26169860
    [No Abstract]   [Full Text] [Related]  

  • 2. Trials of obeticholic acid for non-alcoholic steatohepatitis.
    Armstrong MJ; Newsome PN
    Lancet; 2015 Jul; 386(9988):28. PubMed ID: 26169862
    [No Abstract]   [Full Text] [Related]  

  • 3. Trials of obeticholic acid for non-alcoholic steatohepatitis - Authors' reply.
    Neuschwander-Tetri BA; Van Natta ML; Tonascia J; Brunt EM; Kleiner DE
    Lancet; 2015 Jul; 386(9988):28-29. PubMed ID: 26169861
    [No Abstract]   [Full Text] [Related]  

  • 4. Is obeticholic Acid the solution to nonalcoholic steatohepatitis?
    Wong VW; Wong GL; Chan FK
    Gastroenterology; 2015 Apr; 148(4):851-2. PubMed ID: 25726736
    [No Abstract]   [Full Text] [Related]  

  • 5. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.
    Polyzos SA; Kountouras J; Mantzoros CS
    Metabolism; 2020 Mar; 104():154144. PubMed ID: 31930974
    [No Abstract]   [Full Text] [Related]  

  • 6. NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more?
    Ray K
    Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):1. PubMed ID: 25421586
    [No Abstract]   [Full Text] [Related]  

  • 7. Starting the battle to control non-alcoholic steatohepatitis.
    Ratziu V
    Lancet; 2015 Mar; 385(9972):922-4. PubMed ID: 25468161
    [No Abstract]   [Full Text] [Related]  

  • 8. Obeticholic acid: expanding the therapeutic landscape of NASH.
    Arrese M; Cabrera D; Barrera F
    Ann Hepatol; 2015; 14(3):430-2. PubMed ID: 25864227
    [No Abstract]   [Full Text] [Related]  

  • 9. Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.
    Musso G
    Hepatology; 2015 Jun; 61(6):2104-6. PubMed ID: 25753820
    [No Abstract]   [Full Text] [Related]  

  • 10. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Gawrieh S; Chalasani N
    Clin Liver Dis; 2018 Feb; 22(1):189-199. PubMed ID: 29128056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
    Makri E; Cholongitas E; Tziomalos K
    World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Not Available].
    Pariente A
    Rev Prat; 2015 Feb; 65(2):171. PubMed ID: 25939215
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies.
    Jahn D; Rau M; Wohlfahrt J; Hermanns HM; Geier A
    Dig Dis; 2016; 34(4):356-63. PubMed ID: 27170389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives.
    Gitto S; Guarneri V; Sartini A; Andreone P
    Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):165-171. PubMed ID: 29082798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
    Singh S; Khera R; Allen AM; Murad MH; Loomba R
    Hepatology; 2015 Nov; 62(5):1417-32. PubMed ID: 26189925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.
    Oh H; Jun DW; Saeed WK; Nguyen MH
    Clin Mol Hepatol; 2016 Sep; 22(3):327-335. PubMed ID: 27729634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
    J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: weight change, liver histology and the metabolic effects of obeticholic acid in NASH.
    Eslam M; George J
    Aliment Pharmacol Ther; 2018 Apr; 47(7):1038-1039. PubMed ID: 29512910
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Non-Alcoholic Fatty Liver Disease.
    Scherer A; Dufour JF
    Dig Dis; 2016; 34 Suppl 1():27-31. PubMed ID: 27548081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obeticholic acid: towards first approval for NASH.
    Eslam M; Alvani R; Shiha G
    Lancet; 2019 Dec; 394(10215):2131-2133. PubMed ID: 31813639
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.